Program
betamethasone dipropionate
Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.
Its studies are mostly in Psoriasis · Skin and Connective Tissue Diseases · Dermatitis, Atopic, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LEO Pharma | 180 open or running | phase 4since Nov 3, 2005 | Sep 15, 2005 | none ahead |
| MC2 Therapeutics | 50 open or running | phase 3since Oct 9, 2017 | Oct 9, 2017 | none ahead |
| Glenmark Pharmaceuticals Ltd. India | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
| Huadong Medicine | 10 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | none ahead |
| Primus Pharmaceuticals | 10 open or running | phase 4since Apr 13, 2016 | Apr 13, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Sep 15, 2005.
- Aug 27, 2013Phase 1 study in Psoriasis VulgarisLEO Pharma · NCT01935869 · 224 enrolled · France
- Jan 27, 2015Phase 1 study in Skin and Connective Tissue DiseasesLEO Pharma · NCT02355639 · 16 enrolled · Germany
- Feb 25, 2015Phase 1 study in Dermatitis, AtopicLEO Pharma · NCT02376049 · 30 enrolled · Canada, Israel
- Mar 12, 2015Phase 2 study in Psoriasis VulgarisLEO Pharma · NCT02387853 · 117 enrolled · United States, Netherlands, Poland and more
- Apr 13, 2016Primus Pharmaceuticals’ first study: phase 4 study in Plaque PsoriasisNew to Primus PharmaceuticalsPrimus Pharmaceuticals · NCT02749799 · 45 enrolled · United States
- Nov 22, 2016Phase 1 study in Psoriasis VulgarisLEO Pharma · NCT02973776 · 36 enrolled · France
- Oct 9, 2017MC2 Therapeutics’ first study: phase 3 study in Psoriasis VulgarisNew to MC2 TherapeuticsMC2 Therapeutics · NCT03308799 · 794 enrolled · United States
- Nov 1, 2017Glenmark Pharmaceuticals Ltd. India’s first study: phase 3 study in Scalp PsoriasisNew to Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals Ltd. India · NCT03331523 · 643 enrolled · United States
- Feb 20, 2018Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03462927 · 63 enrolled · United States
- Nov 13, 2018Phase 1 study in VasoconstrictionMC2 Therapeutics · NCT03758365 · 36 enrolled · France
- Jan 10, 2019Phase 3 study in Psoriasis VulgarisMC2 Therapeutics · NCT03802344 · 498 enrolled · Czechia, Germany
- Jan 11, 2019Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03819218 · 7 enrolled · Czechia, Germany
- Jun 16, 2023Phase 3 study in Stable Plaque PsoriasisLEO Pharma · NCT05919082 · 604 enrolled · China
- Dec 11, 2025Huadong Medicine’s first study: phase 3 study in Plaque PsoriasisNew to Huadong MedicineHuadong Medicine · NCT07357831 · 539 enrolled · China
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07357831Plaque Psoriasis · China | 3 | Completed | Huadong Medicine | Aug 6, 2026 | 539 |
| NCT05919082Stable Plaque Psoriasis · China | 3 | Completed | LEO Pharma | Feb 23, 2024 | 604 |
| NCT03819218Psoriasis Vulgaris · Czechia, Germany | 2 | Terminated | MC2 Therapeutics | Dec 11, 2020 | 7 |
| NCT03802344Psoriasis Vulgaris · Czechia, Germany | 3 | Completed | MC2 Therapeutics | Oct 2, 2019 | 498 |
| NCT03758365Vasoconstriction · France | 1 | Completed | MC2 Therapeutics | Nov 23, 2018 | 36 |
| NCT03462927Psoriasis Vulgaris · United States | 2 | Completed | MC2 Therapeutics | Aug 4, 2018 | 63 |
| NCT03331523Scalp Psoriasis · United States | 3 | Completed | Glenmark Pharmaceuticals Ltd. India | Oct 25, 2018 | 643 |
| NCT03308799Psoriasis Vulgaris · United States | 3 | Completed | MC2 Therapeutics | Jun 8, 2018 | 794 |
| NCT02973776Psoriasis Vulgaris · France | 1 | Completed | LEO Pharma | Feb 2017 | 36 |
| NCT02749799Plaque Psoriasis · United States | 4 | Completed | Primus Pharmaceuticals | Jul 2016 | 45 |
| NCT02387853Psoriasis Vulgaris · United States, Netherlands, Poland and more | 2 | Completed | LEO Pharma | Mar 28, 2018 | 117 |
| NCT02376049Dermatitis, Atopic · Canada, Israel | 1 | Completed | LEO Pharma | Jul 2015 | 30 |
| NCT02355639Skin and Connective Tissue Diseases · Germany | 1 | Completed | LEO Pharma | Apr 2015 | 16 |
| NCT01935869Psoriasis Vulgaris · France | 1 | Completed | LEO Pharma | Nov 2013 | 224 |
| NCT01866163Psoriasis Vulgaris · United States | 3 | Completed | LEO Pharma | Oct 2013 | 426 |
| NCT01600222Psoriasis Vulgaris · Canada | 2 | Completed | LEO Pharma | May 2013 | 37 |
| NCT01536938Psoriasis Vulgaris · United States | 2 | Completed | LEO Pharma | Sep 2012 | 303 |
| NCT01536886Psoriasis Vulgaris · United States | 2 | Completed | LEO Pharma | Sep 2012 | 376 |
| NCT00875277Psoriasis Vulgaris · France | 2 | Completed | LEO Pharma | May 2009 | 24 |
| NCT00817219Psoriasis Vulgaris · United States | 2 | Completed | LEO Pharma | Dec 2011 | 33 |
| NCT00263718Psoriasis Vulgaris · Canada, Germany, Ireland and more | 2 | Completed | LEO Pharma | 360 | |
| NCT00248456Psoriasis Vulgaris · China | 4 | Completed | LEO Pharma | 320 | |
| NCT00243464Psoriasis of Scalp · Belgium, Canada, Denmark and more | 3 | Completed | LEO Pharma | 300 | |
| NCT00216879Psoriasis of Scalp · Canada, Denmark, France and more | 3 | Completed | LEO Pharma | 800 | |
| NCT00216840Psoriasis of Scalp · Belgium, Canada, Finland and more | 3 | Completed | LEO Pharma | 1,350 | |
| NCT00216827Psoriasis of Scalp · Canada, Denmark, France and more | 3 | Completed | LEO Pharma | 1,485 |
How it is read
Names in the registry
- “LEO 90100”, 7 entries
- “MC2-01 cream”, 4 entries
- “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
- “MC2-01 Cream”, 2 entries
- “Calcipotriene plus betamethasone dipropionate ointment”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 24 studies
- Skin and Connective Tissue Diseases, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.